Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  BTK inhibitor ACP-196
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
ACP-196 in Combination With Pembrolizumab, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-004, NCI-2015-00489, NCT02213926
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-005, NCI-2015-00945, NCT02351739
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-003, NCI-2015-00538, NCT02362048
ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-001, NCI-2014-00263, NCT02029443
ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-002, NCI-2014-01462, NCT02112526
ACP-196 in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-CL-002, NCI-2014-01691, NCT02157324
An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-003, NCI-2014-02238, NCT02180711
An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-WM-001, NCI-2014-02241, NCT02180724
ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-003, NCI-2014-02555, NCT02296918
Start Over